Innovative Medicine

First published clinical data show prime-boost Ebola vaccine regimen produced an antibody response in 100 percent of healthy volunteers that was sustained 8 months following immunization. An Ebola vaccine is still urgently needed to address the problem of Ebola persistence in affected countries and to prevent future outbreaks. Partners involved in the clinical program for the Ebola vaccine regimen include the Janssen Pharmaceutical Companies of Johnson & Johnson, the London School of Hygiene & Tropical Medicine, the University of Oxford, Inserm, Bavarian Nordic and Europe’s Innovative Medicines Initiative.

Real-world findings show balance of benefit and risk of XARELTO® (rivaroxaban) with respect to ischemic stroke and a reduction in intracranial hemorrhage in routine clinical practice, further confirming the efficacy and safety profile observed in ROCKET AF

Study definitively confirms original results of ROCKET AF and adds to growing body of real-world evidence, informing the safety of XARELTO® in high-risk patients with NVAF

Includes several late breaking and oral presentations from across R&D pipeline Highlights potential of R&D pipeline to deliver several new hepatitis B and C regimens

New data add to growing body of real-world evidence supporting physicians and hospitals in optimizing patient care for those at risk of stroke or blood clots

Findings from this cost savings analysis add to research confirming value of XARELTO® (rivaroxaban) in reducing cost burden to healthcare systems

Intramuscular 2-drug maintenance therapy demonstrates comparable antiviral activity to daily oral 3-drug combination

New approach for early treatment and interception of HPV-induced cancers